(Health-NewsWire.Net, December 22, 2016 ) The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. For more information about this report at http://www.reportsweb.com/chronic-pain-pipeline-review-h2-2016 Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Pain - The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects - The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chronic Pain Request a sample copy at http://www.reportsweb.com/inquiry&RW0001426066/sample Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chronic Pain - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Key Companies profiles Acadia Pharmaceuticals Inc. Adynxx, Inc. Allergan Plc Amorsa Therapeutics Inc. arGEN-X BV Asana BioSciences, LLC AskAt Inc. Astraea Therapeutics, LLC Axsome Therapeutics, Inc. BioDelivery Sciences International, Inc. Biogen Inc Bionomics Limited Camurus AB Cara Therapeutics, Inc. Centrexion Therapeutics Corp ChironWells GmbH Collegium Pharmaceutical, Inc. Crinetics Pharmaceuticals, Inc. Cyclenium Pharma, Inc. Cytogel Pharma, LLC Daewoong Pharmaceutical Co., Ltd. Daiichi Sankyo Company, Limited Dompe Farmaceutici S.p.A. Echo Pharmaceuticals B.V. Egalet Corporation Eli Lilly and Company Elite Pharmaceuticals, Inc. Glenmark Pharmaceuticals Ltd. Grunenthal GmbH Heron Therapeutics, Inc. INSYS Therapeutics, Inc. Johnson & Johnson Kareus Therapeutics, SA KPI Therapeutics, Inc. Kymab Limited Laboratorios Del Dr. Esteve S.A. Lohocla Research Corporation Lpath, Inc. MD Biosciences GmbH Merck & Co., Inc. Moberg Pharma AB Ask for Discount at http://www.reportsweb.com/inquiry&RW0001426066/discount List of Figures Number of Products under Development for Chronic Pain, H2 2016 22 Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016 23 Number of Products under Development by Companies, H2 2016 24 Number of Products under Investigation by Universities/Institutes, H2 2016 31 Comparative Analysis by Late Stage Development, H2 2016 32 Comparative Analysis by Clinical Stage Development, H2 2016 33 Comparative Analysis by Early Stage Products, H2 2016 34 Assessment by Monotherapy Products, H2 2016 111 Assessment by Combination Products, H2 2016 112 Number of Products by Top 10 Targets, H2 2016 113 Number of Products by Stage and Top 10 Targets, H2 2016 113 Number of Products by Top 10 Mechanism of Actions, H2 2016 120 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 120 Number of Products by Top 10 Routes of Administration, H2 2016 127 Number of Products by Stage and Top 10 Routes of Administration, H2 2016 127 Number of Products by Top 10 Molecule Types, H2 2016 129 Number of Products by Stage and Top 10 Molecule Types, H2 2016 129 Purchase Complete Report at http://www.reportsweb.com/buy&RW0001426066/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|